Superior efficacy of nilotinib vs imatinib in patients with chronic myeloid leukemia in chronic phase. ENESTnd and ENESTcmr current results analysis
Journal Title: OncoReview - Year 2013, Vol 3, Issue 1
Abstract
Second generation tyrosine kinase inhibitors can improve the efficacy of treatment and outcome in newly diagnosed patients with chronic myeloid leukemia in chronic phase. The primary endpoint of ENESTnd trial is the comparison and assessment of major molecular response rate at 12 months in patients treated with nilotinib vs imatinib. With 4 years of follow-up, nilotinib demonstrate a superior efficacy over imatinib. In patients with CML-CP, early molecular response is associated with improved outcome. The reduction of bcr/abl level to ≤ 10% at 3 months correlated with significantly higher rates of deep molecular responses and significantly improved progression-free and overall survival. More patients achieved bcr/abl ≤ 10% and ≤ 1% at 3 months on frontline nilotinib vs imatinib. In ENESTcmr trial the percentage of patients with confirmed undetectable bcr/abl transcript or deep molecular response by 12 months achieved under nilotinib therapy in patients with complete cytogenetic response and detectable bcr/abl transcript after more than two-year treatment with imatinib has been evaluated. By 24 months, significantly more patients achieved confirmed undetectable bcr/abl and MR4,5 with switch to nilotinib. Increase in rate of undetectable bcr/abl transcript was 3 times higher on nilotinib vs imatinib from month 12 to 24. Deeper molecular responses after switch to nilotinib will probably create the possibility to participate in TKI-free remission studies for higher number of patients suffering from CML.
Authors and Affiliations
Tomasz Sacha
Keywords
Related Articles
- EP ID EP53202
- DOI -
- Views 230
- Downloads 0
Wczesna odpowiedź molekularna jako kryterium optymalnej odpowiedzi na leczenie przewlekłej białaczki szpikowej inhibitorami kinaz tyrozynowych
Obecnym celem leczenia przewlekłej białaczki szpikowej jest maksymalna redukcja liczby komórek białaczkowych z genem BCR/ABL i umożliwienie jak największej liczbie chorych osiągnięcia długotrwałej, głębokiej odpowiedzi m...
Depression in patients with cancer. Diagnosis and treatment in clinical practice
Comorbidity between depression and cancer is a common condition. It depends on many variables such as cancer location or phase of the illness, but as a rule this situation should not be neglected. The reasons for providi...
Long-standing acromegaly in a patient with a pituitary adenoma not visible on MRI
Introduction: Acromegaly in the course of a pituitary microadenoma or neuroendocrine GHRH-secreting tumour (GHRH, growth hormone-releasing hormone) invisible on MRI is very rare. Objective: To present the difficulties in...
Aktywność fizyczna a nowotwory
Dane epidemiologiczne wskazują, że aktywność fizyczna zmniejsza ryzyko wystąpienia raka piersi i raka jelita grubego. Najprawdopodobniej przyczynia się również do obniżenia ryzyka zachorowania na raka prostaty, trzonu ma...
Idiopathic venous thromboembolism or occult cancer?
The relationship between cancer and an increased incidence of venous thromboembolism (VTE) is well documented. VTE is a common complication of cancer, which usually occurs in the advanced stages of the disease. It often...